4D Molecular Therapeutics, Inc. Common Stock
FDMT4D Molecular Therapeutics, Inc. (FDMT) is a biotechnology company focused on developing targeted gene therapies for various genetic and acquired diseases. Utilizing its proprietary vector platform, 4DMT aims to deliver precise and durable treatments through innovative vector design and delivery methods. The company emphasizes leveraging advanced genetic engineering technologies to create therapies with enhanced specificity and reduced immunogenicity.
Company News
4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.
4D Molecular Therapeutics partnered with Otsuka Pharmaceutical to develop and commercialize 4D-150, a potential transformative therapy for retinal vascular diseases in the Asia-Pacific region, receiving $85 million upfront and potential milestone payments up to $336 million.
GenVivo appointed Dr. Noriyuki Kasahara as Chief Scientific Officer to advance its genetic therapy platform for cancer treatment, leveraging his extensive experience in gene therapy and vector technology research.
4D Molecular Therapeutics reported Q2 2025 financial results with $15 million revenue, exceeding estimates, driven by collaboration income. The company advanced its gene therapy programs for retinal and respiratory diseases, with promising clinical trial progress and a workforce reduction to manage expenses.
4DMT reported Q2 2025 financial results, highlighting accelerated Phase 3 clinical trials for 4D-150 in wet AMD and DME, positive 60-week trial results, and a workforce reduction to drive late-stage execution with $417 million cash runway into 2028.
